Active Filter(s):
Details:
Proceeds from the financing will be used to advance new classes of disease-modifying drugs into the clinic and to further expand the Company’s unique and proprietary discovery platform.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Lightspeed Venture Partners
Deal Size: $51.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 17, 2021